Omeros Corporation (OMER)
NASDAQ:OMER
OMER Stock Chart & Stats
$11.91
-$0.23(-2.31%)
At close: 4:00 PM EST
$11.91
-$0.23(-2.31%)
Day’s Range― - ―
52-Week Range$2.95 - $17.65
Previous CloseN/A
Volume193.12K
Average Volume (3M)1.04M
Market Cap
$827.24M
Enterprise Value$1.06B
Total Cash (Recent Filing)$171.80M
Total Debt (Recent Filing)$239.14M
Price to Earnings (P/E)3.2
Beta1.07
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding71,996,170
10 Day Avg. Volume1,496,561
30 Day Avg. Volume1,040,098
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-102.66
Enterprise Value/Ebitda-9.59
Forecast
1Y Price Target
$40.00Price Target Upside235.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.53
Revenue Forecast (FY)$115.80M
Bulls Say, Bears Say
Bulls Say
Early Commercial Traction And ReimbursementRapid engagement with transplant centers, early formulary wins, and minimal reimbursement friction indicate demand is converting into utilization faster than anticipated, supporting near-term revenue potential.
Pipeline Potential From OncotoX-AMLCompelling preclinical results for OncotoX-AML—showing strong tumor control in animal models and a mutation-agnostic mechanism—support meaningful upside if human trials confirm safety and efficacy.
Regulatory Approval And ExclusivityRegulatory approval as the first approved therapy for transplant-associated thrombotic microangiopathy provides a unique commercial advantage and clear market exclusivity for Yartemlea.
Bears Say
Access And Adoption ConstraintsRequirement to initiate dosing in the inpatient setting, an initial focus on high-risk patients, and gradual familiarity among transplant centers may slow early uptake and constrain market penetration.
Limited Launch TransparencyDisclosure of only limited quantitative details about the Yartemlea launch creates uncertainty around commercial performance and complicates forecasting for investors.
Valuation ExpectationsAnalyst hold ratings note that current stock valuation already incorporates substantial expected Yartemlea sales, which could limit upside even if commercial execution is solid.
Omeros News
OMER FAQ
What was Omeros Corporation’s price range in the past 12 months?
Omeros Corporation lowest stock price was $2.95 and its highest was $17.65 in the past 12 months.
What is Omeros Corporation’s market cap?
Omeros Corporation’s market cap is $827.24M.
When is Omeros Corporation’s upcoming earnings report date?
Omeros Corporation’s upcoming earnings report date is May 20, 2026 which is in 37 days.
How were Omeros Corporation’s earnings last quarter?
Omeros Corporation released its earnings results on Mar 31, 2026. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of -$0.101 by $1.081.
Is Omeros Corporation overvalued?
According to Wall Street analysts Omeros Corporation’s price is currently Undervalued.
Does Omeros Corporation pay dividends?
Omeros Corporation does not currently pay dividends.
What is Omeros Corporation’s EPS estimate?
Omeros Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Omeros Corporation have?
Omeros Corporation has 71,996,170 shares outstanding.
What happened to Omeros Corporation’s price movement after its last earnings report?
Omeros Corporation reported an EPS of $0.98 in its last earnings report, beating expectations of -$0.101. Following the earnings report the stock price went up 14.394%.
Which hedge fund is a major shareholder of Omeros Corporation?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.00 (235.85% Upside)
$40.00 (235.85% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $750.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.07%
12-Months-Change
Fundamentals
Return on Equity
1.71%
Trailing 12-Months
Asset Growth
17.52%
Trailing 12-Months
Company Description
Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by two transformative events: the zaltenibart transaction with Novo Nordisk (large upfront payment, milestones and royalties) and FDA approval plus early commercial traction for YARTEMLEA. Financially, Q4 showed a swing to GAAP net income and robust non-GAAP profitability, materially improved cash position and eliminated several near-term debt obligations. Early launch metrics (payer approvals, rapid delivery, per-vial pricing and initial formulary wins) and pipeline progress add to the constructive outlook. Key risks include noncash volatility from embedded derivative mark-to-market adjustments, remaining 2029 convertible note exposure, incomplete formulary penetration (still early), and a regulatory request delaying one external program. Overall, highlights outweigh the lowlights, with commercialization execution and the Novo transaction materially de-risking the company’s near-term prospects.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$40.00
▲(235.85% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.81% Insiders
7.82% Mutual Funds
11.36% Other Institutional Investors
66.55% Public Companies and Individual Investors